Conference abstractPublished 18 Jul 2016
Science and Business Drivers in Clinical Biomarkers: Focus on Innovation and Quality
Bristol-Myers Squibb Company, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As science-driven businesses, innovative Biopharma companies must manage the inherent risks of being dependent on new discoveries with unknown probability of success. Besides business development activities, combined with various target- and compound- discovery strategies, biomarkers play an increasing role as tools to improve the probability of success. At the same time, the discovery and implementation of biomarkers becomes an additional investment, often with significant risk. On the example of flow cytometry based biomarkers, the presentation will illustrate strategies to develop and implement robust biomarker strategies for maximized return on investment.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectBusiness & Management
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Anka G. Ehrhardt”